Bedaquiline: A new hope in treatment of tuberculosis

Multidrug resistant tuberculosis is defined as resistance to at least isoniazid and rifampicin. Multidrug resistant Tuberculosis is one of the most challenging health problem being faced by the medical fraternity. An urgent need for newer and more effective drugs is relies to combat this Drug Resistant Tuberculosis menance. Bedaquiline, first in a new class of drug , has been approved by the US Food and Drug Association, the first time in 40 years that a drug has been approved that attacked Tuberculosis. In phase III trials Bedaquiline was found to bring about faster culture conversion and significantly more culture conversions. Accordingly, the FDA has approved bedaquiline as part of combination therapy to treat adults with MDR pulmonary TB when other alternatives are not available. Bedaquiline has a promising potential and has a favourable outcome in Drug Resistant Tuberculosis.